Why we feature LLY: Eli Lilly’s GLP-1 obesity/diabetes drugs (Mounjaro, Zepbound) are the largest pharmaceutical category in 50 years. Multi-year revenue compounding potential rivals only the AI semiconductors.
Eli Lilly (LLY) overview
Eli Lilly is a 145-year-old Indianapolis-headquartered pharmaceutical company that became one of the most-watched stocks of the 2020s thanks to its GLP-1 receptor agonist franchise — specifically Mounjaro (tirzepatide for diabetes) and Zepbound (tirzepatide for obesity), the most-prescribed weight-loss medications globally.
Listed on the NYSE under ticker LLY, the company has expanded from a traditional big-pharma valuation multiple to one closer to a high-growth tech stock — driven by GLP-1 revenue compounding at 50–80% year-over-year as manufacturing capacity scales.
What moves LLY
- GLP-1 demand + supply — Mounjaro/Zepbound prescription volumes, manufacturing capacity ramps
- Competitive threats — Novo Nordisk’s Ozempic/Wegovy, pill-form GLP-1 launches, generic biosimilar timelines (mid-2030s)
- Insurance reimbursement — Medicare/Medicaid + commercial insurance coverage decisions move stock 5–10%
- Pipeline announcements — Alzheimer’s drug (donanemab) and oncology pipeline
- FDA + EMA decisions — new indication approvals, label expansions
LLY is less volatile than AI semiconductors (1–2% average daily range) but with multi-year compounding potential. Treated as a “defensive AI” position by many institutional investors.
Where to trade LLY
CFDs via Pepperstone, IC Markets, FxPro. Real shares via eToro, XTB, or Interactive Brokers.